Gail J. Roboz, MD, Discusses Treatment Options for Patients With AML

11/01/2018

Roboz In this 3-part podcast series, Gail Roboz, MD, Professor of Medicine and Director of the Clinical and Translational Leukemia programs at Weill Cornell Medicine and the NewYork-Presbyterian Hospital, discusses current and forthcoming treatment options for patients with AML.

Dr Roboz also talks about the incorporation of drugs newly approved by the FDA into clinical practice, as well as some of the barriers clinicians face in implementing these agents. In addition, she stresses the important role of clinical trials in looking toward the future of AML treatment.

Check out all 3 parts of the AML podcast series with Dr Roboz below!

---

Gail J. Roboz, MD, Discusses the Treatment Landscape for AML

Dr Roboz discusses the current treatment landscape for AML and how it has evolved in recent years.

Listen Here

Using Drugs Newly Approved by the FDA to Treat AML

Dr Roboz discusses the use of newly approved drugs in the treatment of patients with AML, including the challenges clinicians face in implementing these therapies into clinical practice.

Listen Here

Clinical Trials and the Future of Treatment in AML

Dr Roboz discusses the importance of clinical trials for AML drugs, as well as the future outlook of the treatment landscape for AML.

Listen Here

Recent News

News

Initial Low Dose Lenalidomide Over 2 Years Improves Treatment Response Among Non-Transfusion-Dependent Patients With Low-Risk MDS

09/19/2024

Amber Denham ;

An initial treatment of low doses of lenalidomide distributed across 2 years was shown to safely prolong the time to transfusion-dependency and improve responses among non-transfusion-dependent patients with low-risk, del(5q) myelodysplastic...

An initial treatment of low...

09/19/2024

Oncology

News

Combination Therapy Followed by Brentuximab Vedotin Consolidation Demonstrated Safety, Activity Among Patients With CD30-Expressing Peripheral T-Cell Lymphomas

09/19/2024

Amber Denham ;

Cyclophosphamide, doxorubicin, prednisone, brentuximab vedotin, and etoposide, with or without autologous hematopoietic stem-cell transplantation, plus brentuximab vedotin consolidation demonstrated safety and activity for patients with...

Cyclophosphamide, doxorubicin,...

09/19/2024

Oncology

News

FDA Approves First-Line Pembrolizumab Plus Chemotherapy for Patients With Unresectable Advanced Malignant Pleural Mesothelioma

09/18/2024

Stephanie Holland ;

Based on results from the KEYNOTE-483 study, the US FDA has approved pembrolizumab plus pemetrexed and platinum-based chemotherapy as first-line treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma.

Based on results from the...

09/18/2024

Oncology

FDA Alerts

FDA Grants Approval to Ribociclib With Aromatase Inhibitor and Letrozole Co-Pack for Adjuvant Treatment of HR-Positive HER2-Negative High-Risk Breast Cancer

09/17/2024

Gina Tomaine ;

On September 17, 2024, the FDA approved ribociclib with an aromatase inhibitor as well as a ribociclib and letrozole co-pack for the adjuvant treatment of adults with hormone receptor-positive, HER2-negative stage II and III early breast...

On September 17, 2024, the FDA...

09/17/2024

Oncology

News

Management of Adverse Events Associated With Selumetinib for Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

09/17/2024

Allison Casey ;

A panel of experts provided consensus recommendations on prevention, early detection, and management of adverse events potentially associated with selumetinib among pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas.

A panel of experts provided...

09/17/2024

Oncology

News

New Risk Stratification Model Provides Prognostic Data on Survival Post-AlloHCT for Older Patients With AML and High-Risk MDS

09/17/2024

Amber Denham ;

The AML60+ classification system demonstrated efficacy in providing prognostic information for intensively treated patients 60 years and older with AML and high-risk MDS, and in identifying patients who would benefit from chemotherapy and...

The AML60+ classification system...

09/17/2024

Oncology

Conference Coverage

Berlrestotug Added to Dostarlimab Demonstrates Antitumor Activity in PD-L1-High Locally Advanced or Metastatic Non-Small Cell Lung Cancer

09/16/2024

Stephanie Holland ;

Results from the phase 2 GALAXIES Lung-201 study show the addition of berlrestotug to dostarlimab demonstrates antitumor activity among patients with PD-L1-high locally advanced or metastatic non-small cell lung cancer.

Results from the phase 2...

09/16/2024

Oncology

FDA Approval

FDA Approves Subcutaneous Formulation of Atezolizumab for Patients With Certain Solid Tumors

09/13/2024

Stephanie Holland ;

On September 12th, 2024, the US FDA approved subcutaneous coformulation of atezolizumab plus hyaluronidase for adult patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part...

On September 12th, 2024, the US...

09/13/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers

09/12/2024

Allison Casey ;

According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.

According to results of the...

09/12/2024

Oncology

News

Sacituzumab Govitecan Shows Potential Among Patients With Locally Advanced or Metastatic Urothelial Cancer

09/10/2024

Stephanie Holland ;

According to results from Cohort 2 of the phase 2 TROPHY-U-01 trial, sacituzumab govitecan demonstrated clinically meaningful antitumor activity among patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible...

According to results from Cohort...

09/10/2024

Oncology